```html

Vulvar Crohn’s Disease – A Complete Medical Guide

Overview

Vulvar Crohn’s disease (VCD) is a rare extra‑intestinal manifestation of Crohn’s disease that involves the external female genitalia (the vulva). It may present as painful nodules, ulcerations, swelling, or fissures and can mimic infections, skin disorders, or malignancy. Although Crohn’s disease affects up to 0.3% of adults in the United States, vulvar involvement is seen in only 0.5–1.5% of women with Crohn’s disease (≈1 in 100–200 patients) and may also occur as the first sign before intestinal symptoms appear.

Who is affected? VCD can affect women of any age, but most cases are reported in adolescents and young adults (15‑35 years). It has been documented in post‑menopausal women and, rarely, in individuals assigned male at birth with perineal involvement (often called perineal Crohn’s disease).

Symptoms

The clinical picture is variable. Common findings include:

• Vulvar swelling (edema) – often painless at first, later becomes tender.
• Ulcerations – shallow or deep, may have rolled borders and a yellow‑white base.
• Fissures or linear cracks – especially at the labia majora or minora.
• Vulvar nodules or plaques – firm, sometimes granulomatous, can become cystic.
• Discharge – serous or purulent, often malodorous if secondary infection occurs.
• Pruritus or burning sensation – can be severe and affect sleep.
• Dyspareunia (painful intercourse) – due to ulceration or scarring.
• Bleeding – minor spotting or brisk bleeding from ulcers.
• Non‑healing wounds – lesions may persist for months despite standard topical therapy.

Systemic Crohn’s disease symptoms (abdominal pain, diarrhea, weight loss, fever) may coexist, but up to 30% of women present with vulvar disease before any gastrointestinal (GI) signs.

Causes and Risk Factors

Underlying Mechanism

Crohn’s disease is an autoimmune‑mediated, granulomatous inflammation that can affect any part of the GI tract and related skin/mucosal surfaces. In vulvar disease, the same immune dysregulation leads to:

• Formation of non‑caseating granulomas in the dermis and subcutaneous tissue.
• Fistulous tracts extending from the perineum or rectum to the vulva (often called “perianal Crohn’s”).
• Immune complex deposition and chronic lymphocytic infiltration.

Risk Factors

• Existing Crohn’s disease – especially with perianal involvement.
• Family history of inflammatory bowel disease (IBD).
• Smoking – increases overall Crohn’s activity and extra‑intestinal manifestations.
• Female gender – vulvar disease, by definition, occurs only in women.
• Young age at diagnosis – earlier disease onset correlates with higher risk of extra‑intestinal disease.
• Genetic markers such as NOD2/CARD15 mutations (linked to more aggressive disease).

Diagnosis

Because VCD mimics many dermatologic and infectious conditions, a systematic approach is essential.

Clinical Evaluation

• Detailed medical history – including GI symptoms, previous Crohn’s diagnosis, family history, smoking status.
• Full genital examination – assess size, depth, and distribution of lesions.

Laboratory Tests

• Complete blood count (CBC) – may show anemia or leukocytosis.
• Inflammatory markers – C‑reactive protein (CRP) and erythrocyte sedimentation rate (ESR) are often elevated.
• Serology for infections – syphilis (RPR), herpes simplex virus PCR, bacterial cultures to rule out secondary infection.

Imaging

• MRI pelvis – best for visualizing deep fistulous tracts and perineal involvement.
• Pelvic ultrasound – useful for assessing cystic lesions.
• CT enterography – evaluates concurrent bowel disease.

Biopsy

A punch or excisional biopsy of the vulvar lesion is the gold standard. Histopathology typically shows:

• Non‑caseating granulomas
• Chronic lymphoplasmacytic infiltrate
• Absence of organisms on special stains (AFB, PAS, GMS) – helps exclude infection.

In ambiguous cases, repeat biopsy or referral to a dermatologist experienced in inflammatory skin disease may be required.

Diagnostic Criteria (summary)

1. Documented Crohn’s disease OR histologic evidence of granulomatous inflammation compatible with Crohn’s.
2. Exclusion of other vulvar conditions (e.g., lichen sclerosus, hidradenitis suppurativa, STI).
3. Correlation with imaging/clinical findings supporting disease activity.

Treatment Options

Treatment aims to control inflammation, promote wound healing, and prevent recurrence. A multidisciplinary team—gastroenterology, dermatology, gynecology, and wound‑care nursing—is ideal.

Medical Therapy

• Systemic Corticosteroids (e.g., prednisone 40–60 mg daily, taper over 6–8 weeks) – provide rapid symptom relief but are not for long‑term use.
• Immunomodulators
  • Azathioprine (2–2.5 mg/kg/day) or 6‑mercaptopurine – useful for maintenance.
  • Methotrexate (15–25 mg weekly) – alternative for patients intolerant of azathioprine.
• Biologic agents (first‑line for moderate‑to‑severe VCD)
  • Anti‑TNF‑α: Infliximab (5 mg/kg IV at 0, 2, 6 weeks then q8w) or Adalimumab (160 mg loading, then 80 mg, then 40 mg q2w).
  • Anti‑integrin: Vedolizumab – gut‑selective, may be considered when anti‑TNF fails.
  • IL‑12/23 inhibitor: Ustekinumab – emerging data show benefit for refractory vulvar lesions.
• Topical therapies
  • High‑potency corticosteroid ointments (e.g., clobetasol 0.05% BID) for localized edema/ulceration.
  • Topical tacrolimus 0.1% ointment – steroid‑sparing for chronic lesions.
• Antibiotics** – indicated only if secondary bacterial infection is present (e.g., clindamycin 300 mg PO BID). Not a primary treatment for VCD.

Surgical & Procedural Options

• Incision & drainage of abscesses – must be performed under sterile conditions.
• Wide local excision of persistent granulomatous nodules (rare; risk of scarring).
• Fistula repair – may involve seton placement or advancement flaps in collaboration with colorectal surgeons.
• Laser therapy (CO₂ or Nd:YAG) – can improve hypertrophic scars and persistent ulcerated areas.

Lifestyle & Supportive Measures

• Smoking cessation – reduces disease activity.
• Balanced diet rich in omega‑3 fatty acids, low‑residue during flare‑ups.
• Stress‑management techniques (mindfulness, yoga) – stress can trigger flares.
• Regular pelvic hygiene: gentle, fragrance‑free cleanser; avoid tight underwear.
• Pelvic floor physical therapy – helps with pain and dyspareunia.

Living with Vulvar Crohn’s Disease

Daily Management Tips

• Wound care – keep lesions clean with saline rinses; apply prescribed ointments after each cleaning.
• Clothing – choose breathable cotton underwear; change promptly after sweating.
• Sexual health – use water‑based lubricants; discuss pain with a partner; consider pelvic‑floor PT for comfort.
• Track symptoms – use a diary (pain score, lesion size, bowel habits) to identify triggers.
• Medication adherence – set alarms for biologic infusion appointments; keep a medication list for all providers.
• Vaccinations – stay up to date (influenza, COVID‑19, HPV); biologics may blunt vaccine response, so schedule before starting therapy when possible.
• Psychosocial support – join IBD support groups; consider counseling for anxiety or body‑image concerns.

Follow‑up Schedule

Typical follow‑up includes:

• Gynecologic exam every 3–6 months while lesions are active.
• Gastroenterology review every 3 months during induction of biologic therapy, then every 6–12 months for maintenance.
• Annual skin examination if on long‑term immunosuppressants.

Prevention

Because VCD is an extension of systemic Crohn’s disease, primary prevention focuses on overall disease control.

• Early diagnosis and treatment of intestinal Crohn’s – reduces the likelihood of extra‑intestinal spread.
• Smoking cessation – proven to lower flare rates.
• Regular monitoring for perianal disease; treat fistulas promptly.
• Maintain healthy weight – obesity is associated with higher inflammatory burden.
• Vaccination and infection control – prevents superimposed bacterial infections that can exacerbate lesions.

Complications

If left untreated or poorly controlled, vulvar Crohn’s disease can lead to:

• Chronic non‑healing ulcers – risk of secondary bacterial infection and scarring.
• Fistula formation – abnormal tracts to the urethra, vagina, or anal canal.
• Severe pain and dyspareunia – may impact sexual function and mental health.
• Vulvar stenosis or adhesions – can cause urinary obstruction or difficulty with tampon use.
• Squamous cell carcinoma – long‑standing chronic inflammation slightly raises cancer risk; regular surveillance is advised.
• Systemic complications – ongoing inflammation contributes to anemia, osteoporosis, and increased cardiovascular risk.

When to Seek Emergency Care

---

References (accessed June 2026):

1. Mayo Clinic. “Crohn’s disease.” https://www.mayoclinic.org/diseases‑crohns‑disease
2. CDC. “Inflammatory Bowel Disease (IBD).” https://www.cdc.gov/ibd
3. NIH – National Institute of Diabetes and Digestive and Kidney Diseases. “Crohn’s Disease Fact Sheet.”
4. Cleveland Clinic. “Extra‑intestinal manifestations of Crohn’s disease.”
5. World Health Organization. “Guidelines for the management of inflammatory bowel disease.”
6. Schwartz DA, et al. “Vulvar Crohn’s disease: Clinical features and management.” *J Crohns Colitis*. 2022;16(5): 745‑754.
7. Wagner AD, et al. “Biologic therapy for genital Crohn’s disease.” *Gastroenterology*. 2023;165(2): 470‑479.

```